| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
University of Rochester Cancer Center and the Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642 [J. M. B.], and the Division of Biostatistics and Epidemiology, Harvard School of Public Health and the Sidney Farber Cancer Institute, Boston, Massachusetts 02115 [C. B. B.]
A study of over 300 adult patients with acute myeloid leukemia has been completed by member institutions of the Eastern Cooperative Oncology Group. A complete remission rate of 51% was achieved. The FAB classification was used with an overall concordance of 61% between investigators and the repository center. Acute monocytic leukemia (M5) and acute erythroleukemia (M6) accounted for 12% of the cases accessioned and had the worst median survival with no patients surviving 2 years. The longest response duration occurred in hypergranular promyelocytic leukemia (M3).
1 Presented at the Conference on Cell Markers in Acute Leukemia, March 4 and 5, 1980, Bethesda, Md. Supported by USPHS Grants CA 11083, CA 11198, and CA 23318 from the National Cancer Institute.
2 To whom requests for reprints should be addressed, at 601 Elmwood Avenue, Rochester, N. Y. 14642.
for the Eastern Cooperative Oncology Group
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |